Neutral-atom arrays are a rapidly emerging platform to create quantum computers. In a foundational study led by graduate students Aaron Holman and Yuan Xu from the Will and Yu labs, respectively, the ...

Google's Danny Sullivan said on the Search Off the Record podcast that was published yesterday that Google does not want you to turn your content into bite-sized chunks to rank well in LLMs. He said, ...

Recent Exact Sciences Corporation financials show accelerating revenue growth and stable margins, despite ongoing investments in screening and MRD. While EXAS maintains leadership in stool-based CRC ...

Microsoft and Linux are adding AI and Rust to their pipelines. Microsoft is leaning much harder into AI development than Linux. Both are expanding Rust, but neither OS will be fully Rust soon.

Back in July, Microsoft revealed how it is heavily incorporating AI into its development workflows. It talked about its in-house AI-powered coding assistant being leveraged for code reviews of over ...

TOMAH, Wis. (WKBT) -- Ho-Chunk Nation will open its first independently owned and operated movie theater Friday, bringing a state-of-the-art cinematic experience to the Tomah community. Ho-Chunk ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business. This marks one of Abbott's largest deals ...

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...

The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry. A strategic investor is ...